ArticleScience advances2025
Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells.
Abstract read
In one paragraph
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cellular senescence and regulated cell death in cancer: mechanisms, cross-regulatory networks and therapeutic implications.Journal of hematology & oncology · 2026Review
- Article
- Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics.Molecular cancer · 2026Review
- Stem cell-derived extracellular vesicles and artificial nanovesicles: a translational framework for cell-free wound repair.NPJ Regenerative medicine · 2026Review
- Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Heparanase-Loaded CAR T Extracellular Vesicles Remodel the Colorectal Tumour Microenvironment and Boost T Cell Antitumor Immunity.Journal of extracellular vesicles · 2026Article
- Cargo-driven extracellular vesicles as pharmaceutical nanocarriers: A pharmaceutics-oriented comparison of animal exosomes and plant-derived exosome-like nanoparticles.International journal of pharmaceutics: X · 2026Review
- Small extracellular vesicles in tumor metabolism and immune escape: biomarkers and therapeutic opportunities.Molecular biology reports · 2026Review
- From hotspots to hotspaces: Cascaded photonic-plasmonic coupling for SERS-based deep profiling of whole small extracellular vesicles.Science advances · 2026Article
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- Novel insights into extracellular vesicles: An update on biomolecules, immunomodulation and clinical strategies in skin melanoma.Clinical and translational medicine · 2026Review
- Microneedle-based delivery of cell membrane vesicles as IL-17RA decoys for Psoriasis treatment.Journal of nanobiotechnology · 2026Article
- DR5 CAR-T cells target melanoma and suppress MDSCs with minimal toxicity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Bioengineering of extracellular vesicles with scaffold proteins for drug delivery.Journal of nanobiotechnology · 2026Review
- Small extracellular vesicles as system-level regulators and predictive biomarkers in breast cancer progression and chemoresistance.Frontiers in pharmacology · 2026Review
- Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Nature-Inspired Nanostructures from Multiple-Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor-Targeted Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The Dual Role of the TRAIL-DR5 Signaling Axis in Cardiovascular Disease: From Molecular Mechanisms to Targeted Therapies.Biologics : targets & therapy · 2025Review
- Bottom-up Biomaterial strategies for creating tailored stem cells in regenerative medicine.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Yeye GuoDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8352-1121
Huaishan WangDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-8686-4357
Shujing LiuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2958-093X
Xiaogang ZhangDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2280-403X
Xingyue ZhuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Lili HuangDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Wenqun ZhongDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-1633-6962
Lei GuanDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yeqing ChenMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0002-5602-3311
Min XiaoMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
Lingling OuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jingbo YangDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xiang ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 41000, China.ORCID 0000-0001-8187-636X
Alexander C HuangDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-0099-0492
Tara MitchellDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ravi AmaravadiDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Giorgos KarakousisDepartment of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
John MiuraDepartment of Surgery, University of Pennsylvania, Philadelphia, PA 19104, USA.
Lynn SchuchterDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ahron FlowersDepartment of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Qiuxian ZhengMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0001-5609-7380
Haiwei MouMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.
Phyllis GimottyDepartment of Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-3850-9799
Meenhard HerlynMolecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.ORCID 0000-0003-0839-0739
Wei GuoDepartment of Biology, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9251-0360
Xiaowei XuDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-4098-7690
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MTumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2008 to 2023
$37.1MTargeting exosomal PDL1 to improve immunotherapyP50CA261608 · NCI · WISTAR INSTITUTE · PI VILLANUEVA, JESSIE · 2021 to 2025
$11.3MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MMolecular Basis and Regulatory Mechanisms of Exosome SecretionR35GM141832 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI WEI GUO · 2021 to 2026
$3.9MGamma delta T cell based melanoma therapiesR01CA258113 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Meenhard F Herlyn, Xiaowei Xu · 2022 to 2026
$3.3MRole of progenitor exhausted CD8 T cells and the progenitor niche in anti-PD1 efficacyR01CA273018 · NCI · UNIVERSITY OF PENNSYLVANIA · PI HUANG, ALEXANDER · 2022 to 2025
$2.6MDesigner extracellular vesicles for cancer therapyR01CA284182 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Xiaowei Xu · 2024 to 2026
$1.9MNCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA016520NCI NIH HHS P50 CA174523NCI NIH HHS P50 CA261608NCI NIH HHS R01 CA258113NCI NIH HHS R01 CA273018NCI NIH HHS R01 CA284182NIGMS NIH HHS R35 GM141832
Abstract
Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from natural killer cells. PDGFR transmembrane domain delivers DR5-scFvs to the surface of sEVs. DR5-scFv sEVs rapidly induce apoptosis of different types of DR5
Indexed as
Extracellular VesiclesNeoplasmsReceptors, TNF-Related Apoptosis-Inducing LigandSingle-Chain AntibodiesStromal CellsAnimalsApoptosisCell Line, TumorFemaleHumansMiceMyeloid-Derived Suppressor CellsTumor MicroenvironmentXenograft Model Antitumor AssaysReceptors, TNF-Related Apoptosis-Inducing LigandSingle-Chain Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.